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LATS1 but not LATS2 represses autophagy
by a kinase-independent scaffold function
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Autophagy perturbation represents an emerging therapeutic strategy in cancer. Although
LATS1 and LATS2 kinases, core components of the mammalian Hippo pathway, have been
shown to exert tumor suppressive activities, here we report a pro-survival role of LATS1 but
not LATS2 in hepatocellular carcinoma (HCC) cells. Speciﬁcally, LATS1 restricts lethal
autophagy in HCC cells induced by sorafenib, the standard of care for advanced HCC
patients. Notably, autophagy regulation by LATS1 is independent of its kinase activity.
Instead, LATS1 stabilizes the autophagy core-machinery component Beclin-1 by promoting
K27-linked ubiquitination at lysine residues K32 and K263 on Beclin-1. Consequently, ubi-
quitination of Beclin-1 negatively regulates autophagy by promoting inactive dimer formation
of Beclin-1. Our study highlights a functional diversity between LATS1 and LATS2, and
uncovers a scaffolding role of LATS1 in mediating a cross-talk between the Hippo signaling
pathway and autophagy.
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Liver cancer is the second leading cause of cancer-relatedmortality with hepatocellular carcinoma (HCC), represent-ing about 90% of all cases of primary liver cancer1. Viral
infections (hepatitis B or C), alcohol abuse, and metabolism-
induced non-alcoholic fatty liver disease are major risk factors for
HCC incidence1. Unlike other malignancies, HCC is often diag-
nosed only at advanced stages, where liver transplantation, sur-
gical therapies, and resection are not available. Sorafenib (Srf), a
multi-kinase inhibitor, is the standard-of-care treatment and the
only effective systemic option for late-stage HCC, however, only
with an average increased overall patient survival of ~3 months2.
Apparently, HCC cells acquire resistance to Srf therapy. There-
fore, understanding how HCC cells respond to Srf is important to
improve the efﬁcacy of Srf-based therapy in HCC patients;
notably, to overcome the development of evasive resistance to Srf
therapy.
Macroautophagy (hereafter referred to as autophagy) is a self-
digestion process that targets the cytoplasmic components to the
lysosomes for nutrient recycling in response to cellular stress and
starvation3. Autophagy has been shown to play dual roles in
tumor initiation and tumor progression4,5. Autophagy deﬁciency
promotes tumor initiation but represses malignant tumor pro-
gression and, as a consequence, autophagy plays a conﬂicting role
in cancer therapy, including the treatment of HCC with Srf6.
Although acute treatment of HCC cells with Srf induces a lethal
version of autophagy7–9, a survival version of autophagy is likely
to mediate the adaptive response to Srf and promotes cell viability
in Srf-resistant cells10,11. Thus, the biological consequence of
autophagy activation in response to therapy is context-dependent
and the mechanistic understanding of how autophagy is regulated
in cancer appears of great importance to optimize therapeutic
interventions.
The Hippo signaling pathway has emerged as a major growth
control network regulating cell death, proliferation, and differ-
entiation12,13. Activated Hippo or MAP4Ks phosphorylate and
activate the downstream kinases Large Tumor Suppressor 1 and 2
(LATS 1 and 2), which in turn phosphorylate and inactivate the
Hippo signaling transducers YAP and TAZ14. In short, Hippo
signaling critically relies on a variety of protein kinase activities
and protein phosphorylation events.
Here we report a kinase activity-independent role of LATS1,
but not LATS2, in regulating therapy-induced autophagy in HCC
cells. The results indicate that this scaffolding function of LATS1
plays a critical role in the regulation of autophagy and in therapy
response of HCC cells and potentially other cancer type cells.
Results
Repression of Srf-induced cell death by LATS1. The mamma-
lian Hippo pathway has been linked to tumorigenesis and therapy
resistance15–17. While examining the role of the Hippo signaling
pathway in the response of HCC cells to Srf treatment, we dis-
covered an unexpected cell survival role of LATS1. Small inter-
fering RNA (siRNA)-mediated ablation of LATS1, but not of
LATS2, resulted in an increase of Srf-induced apoptotic cell death
and a statistically signiﬁcant reduction of viability in different
HCC cell lines (Fig. 1a and Supplementary Fig. 1a, b), indicating a
potential functional diversity between LATS1 and LATS2 in
HCC. The pro-survival function of LATS1 in Srf-treated HCC
cells was further validated by stable short hairpin RNA (shRNA)-
mediated depletion of LATS1 expression (Fig. 1b and Supple-
mentary Fig. 1c–e). Moreover, although shRNA-mediated loss of
LATS1 did not affect primary tumor growth of HCC cells in
xenotransplanted immunodeﬁcient mice, it signiﬁcantly reduced
tumor growth under Srf treatment (Fig. 1c and Supplementary
Fig. 1f). Furthermore, we conﬁrmed a pro-survival role of LATS1
in HCC patient-derived ex vivo organoid lines18 (Fig. 1d).
To further examine the role of LATS1 in Srf resistance in HCC,
we established Srf-resistant Huh7 cells by (1) step-wise increasing
the concentration of Srf to induce resistance (Huh7-IR cells) or (2)
by adding a consistent high concentration of Srf to induce
resistance (Huh7-CR cells) (Fig. 1e and Supplementary Fig. 1g, h).
Analysis of LATS1 protein expression revealed an upregulation in
these resistant cells in comparation to the parental line (Fig. 1f).
More importantly, knockdown of the upregulated LATS1 in
resistant cells led to a reduction of cell viability with decreased
number of cell colonies (Fig. 1g).
We next investigated the clinical signiﬁcance of these
observations. Expression of the LATS1 and LATS2 tumor
suppressors has been reported to be deregulated in several types
of cancers19. We ﬁrst analyzed the expression of LATS1/2 in HCC
patient samples in comparison with healthy liver tissues in The
Cancer Genome Atlas (TCGA) database20. Surprisingly, LATS1
messenger RNA levels were found to be signiﬁcantly higher,
whereas LATS2 mRNA levels were rather lower in HCC patient
samples as compared with normal liver controls (Fig. 1h, i).
Prognostic analysis of the HCC patient data in the TCGA liver
HCC database further supported the notion of a pro-tumorigenic
role of LATS1; high levels of LATS1 mRNA correlated with poor
overall and disease-free HCC patient survival (Fig. 1j, k).
Strikingly, the opposite trend was observed with LATS2, where
high LATS2 mRNA levels correlated with better survival in HCC
patients, although with marginal signiﬁcance (Supplementary
Fig. 1i, j). Finally, the correlation between LATS1 mRNA
expression and Srf response was explored in a local patient
cohort where serial and paired tumor and non-tumor biopsies
were taken and analyzed before and during Srf therapy. Although
not with signiﬁcance, a trend of higher LATS1 mRNA expression
was found in pre-treatment tumor tissues in patients not
responding to Srf therapy as compared with Srf therapy
responders (Fig. 1l, left panel). Most important, signiﬁcantly
higher LATS1 mRNA expression was found in Srf non-
responders as compared with Srf responders after Srf treatment
(Fig. 1l, right panel), suggesting that LATS1 mRNA levels may
represent a new biomarker to predict Srf response in HCC
patients.
Together, these ﬁndings demonstrate a role of LATS1, but not
LATS2, in therapy response of HCC. Notably, they identify an
unexpected HCC cell survival function of the tumor suppressor
kinase LATS1 in response to Srf treatment.
Kinase activity-independent regulation of autophagy by
LATS1. LATS1 and LATS2 kinases are known to redundantly
mediate the phosphorylation-induced inactivation of the tran-
scription factors YAP/TAZ21. Our results indicate a functional
diversity between LATS1 and LATS2 in regulating Srf resistance.
We thus assessed whether LATS1’s canonical kinase activity was
required for its role in cell viability. Analysis of partial resistant
HCC cells22 forced to express either a wild-type (WT) or a
kinase-dead (KD) version of LATS1 revealed a reduction of cell
death in cells overexpressing both forms of LATS1 (Supplemen-
tary Fig. 1k). Moreover, a similar effect was observed with siRNA-
resistant cDNAs mediating the re-expression of a WT or a KD
version of LATS1 in LATS1-knockdown cells (Supplementary
Fig. 1l, m). Analysis of the activity status of the Hippo transducer
YAP conﬁrmed RNA interference (RNAi)-mediated ablation of
LATS1 and/or LATS2 resulted into an increase of total YAP
protein levels and potentially YAP activity, as monitored by
immunoblotting and phos-tag gel electrophoresis (Supplementary
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Fig. 1n). Together, these results indicate that the pro-survival role
of LATS1 is independent of its kinase activity.
To uncover the molecular mechanism underlying the pro-
survival function of LATS1 in HCC, we performed transcriptomic
analysis by RNA sequencing (RNA-seq) of the HCC cell line
Huh7 in response to Srf and siRNA-mediated ablation of LATS1
or LATS2 expression. In line with a speciﬁc role of LATS1 in
regulating Srf-induced cell death, LATS1 deﬁciency led to a
dramatic change in global transcription as compared to the loss of
LATS2 (Supplementary Fig. 2a). Pathways analysis identiﬁed
phagosomal pathways highly expressed in LATS1-deﬁcient cells
(Supplementary Fig. 2b). Gene set enrichment analysis (GSEA)
revealed that the changes in gene expression caused by the loss of
LATS1 correlated positively with the regulation of autophagy in
the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and
Genomes (KEGG) databases (Supplementary Fig. 2c), and also in
a dataset derived from Lats1/2-deﬁcient murine hepatoblasts
(Supplementary Fig. 2d).
Srf is well-known to promote autophagy induction and
autophagic ﬂux9. Thus, we investigated the effect of LATS1 on
autophagy induction in HCC cells upon Srf treatment. Indeed,
siRNA-mediated knockdown of LATS1, but not LATS2, resulted
in a signiﬁcant increase of LC3B puncta at both basal level and
upon Srf stimulation in HCC cells (Fig. 2a, b and Supplementary
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Fig. 3a, b). Increased LC3B puncta could result from either
enhanced autophagy induction or impaired autophagic ﬂux. To
discriminate between these possibilities, we ﬁrst quantiﬁed the
LC3B puncta number upon treatment with the lysosomal
inhibitor baﬁlomycin A1 (Baf) and with Srf. LC3B puncta
numbers were found higher in LATS1-deﬁcient, but not in
LATS2-deﬁcient cells, as compared with siControl-transfected
cells (Fig. 2a, b and Supplementary Fig. 3a, b), indicating that the
loss of LATS1 efﬁciently promoted autophagy induction.
Furthermore, we analyzed the effect of LATS1 in autophagic
ﬂux. Immunoblotting for p62, also known as SQSTM1 and a
marker for autophagic ﬂux, revealed a signiﬁcant reduction of its
levels upon loss of LATS1 but not LATS2, indicating that the
speciﬁc loss of LATS1 also induced a higher autophagic ﬂux
activity (Supplementary Fig. 3c). Blocking autophagic ﬂux by
chloroquine (CQ) prevented the reduction of p62 upon LATS1
deﬁciency, indicating that LATS1-mediated p62 downregulation
occurred via the activation of autophagic ﬂux (Supplementary
Fig. 3d). Conversely, the forced expression of LATS1 inhibited
Srf-induced degradation of p62, suggesting a restrictive role of
LATS1 in autophagic ﬂux (Fig. 2c and Supplementary Fig. 3e).
These results suggest that LATS1, but not LATS2, represses
autophagy induction and autophagic ﬂux in HCC cells at baseline
and in response to Srf treatment.
Given the notable difference between the functional contribu-
tion of LATS1 and LATS2 to autophagy regulation described
above, we addressed whether the functional contribution of
LATS1 to autophagy regulation depended on its kinase activity.
Strikingly, overexpression of both WT and a KD version of
LATS1 inhibited Srf-induced p62 degradation, indicating a kinase
activity-independent role of LATS1 in autophagy regulation
(Fig. 2c). Likewise, exogenously expressed siRNA-refractory WT
and KD LATS1 prevented p62 degradation induced by the loss of
endogenous LATS1 expression (Fig. 2d, e). Together, the data
indicate that LATS1, but not LATS2, represses autophagy in HCC
cells by a kinase-independent mechanism.
We next assessed whether the LATS1-mediated prevention of
Srf-induced autophagy in HCC cells was speciﬁc for Srf treatment
or represents a generic effect in response to other molecularly
targeted therapies. Indeed, we observed a similar effect of LATS1
on regulation of autophagy and cell death in response to
cabozantinib and sunitinib, where knockdown of LATS1 resulted
in higher autophagic ﬂux as monitored by p62 degradation and
increased cell death (Supplementary Fig. 3f). As we observed a
general trend of downregulation of endogenous LATS1 in
response to targeted therapies in HCC (Figs. 1a and 2c, and
Supplementary Fig. 3e, f), we further investigated potential
degradation pathways of LATS1 under these stresses. Interest-
ingly, blockade of autophagy as well as the proteasomal
degradation pathway stabilized LATS1 protein, suggesting that
Srf treatment can induce autophagic and proteasomal degrada-
tion of LATS1 (Supplementary Fig. 3g), and highlighting a
potential feedback loop between LATS1 and autophagy
regulation.
Next, we determined the direct impact of enhanced autophagy
on reduced cell viability in the context of loss of LATS1
expression. We ﬁrst tested whether the genetic inhibition of
autophagy could overcome the enhanced cell death promoted by
the loss of LATS1 expression. Repression of autophagy by siRNA-
mediated ablation of ATG5 expression, a factor essential for
autophagy initiation23 (Supplementary Fig. 4a), efﬁciently pre-
vented cell death and decreased cell viability induced by siRNA or
shRNA-induced ablation of LATS1 expression and Srf exposure
(Supplementary Fig. 4b–d). Next, we pharmacologically blocked
autophagy by CQ and found that CQ could partially revert the
reduced colony formation upon loss of LATS1, supporting a
death-promoting role of LATS1 deﬁciency-induced autophagy in
response to Srf (Supplementary Fig. 4e, f).
In addition to many tyrosine kinase receptors, Srf also targets
RAF kinases. Given a direct LATS1-RAF cross-talk24 and a
potential crucial role of the mitogen-activated protein kinase
(MAPK) signaling pathway in autophagy25, we further examined
the role of RAF-MAPK signaling in LATS1-mediated Srf
response using the MEK inhibitor PD0325901. Although MEK
inhibition alone did not have a signiﬁcant impact on autophagy
and cell death, its combination with Srf resulted in increased
autophagy and cell death upon RNAi-mediated ablation of
LATS1 expression (Supplementary Fig. 4g).
Together, the results demonstrate a kinase activity-
independent role of LATS1, but not LATS2, in restricting
autophagy and consequently preventing Srf-induced cell death
in HCC cells.
A general role of LATS1-mediated inhibition of autophagy.
Increased autophagy has been broadly implicated in cancer
therapy, especially in targeted therapy6. To assess whether
LATS1-mediated autophagy repression exerts a general function
in various types of cancer therapy, we analyzed vemurafenib-
mediated BRAF inhibition (BRAFi) in BRAFV600E-mutant
A2058 melanoma cells. Interestingly, similar patterns of
Fig. 1 A pro-survival role of LATS1 in HCC cells in response to sorafenib treatment. a Huh7 cells were transfected with indicated siControl and treated
with DMSO vehicle or sorafenib (Srf) for 72 h. Cell death was analyzed by immunoblotting with indicated antibodies. Results represent three independent
experiments. b Colony formation was determined in Huh7 cells expressing either shControl (shRNA targeting LacZ) or a shRNA against LATS1 and
exposed to sorafenib. Results represent three independent experiments. c Huh7 cells either expressing shControlor sh LATS1 were implanted into the ﬂank
of NSG mice. The mice were treated with placebo or sorafenib and tumor volumes were measured. n= 7–9 for each treatment cohort. Statistical
signiﬁcance was calculated using the R package compareGrowthCurves. d Loss of LATS1 expression results in impaired viability of HCC organoid lines in
response to sorafenib (Srf). Results were pooled from three to ﬁve independent experiments. Statistical signiﬁcance was calculated using two-tailed, paired
t-test. e Schematic illustration of establishment of sorafenib-resistant cells by (1) step-wise increasing sorafenib concentration (Huh7-IR cells) and (2)
consistent high concentration (Huh7-CR cells). f Analysis of LATS1 protein expression in sorafenib-resistant cells. Parental (Huh7p) and IR/CR cells were
treated with Sorafenib (5 μM) for24 h. Cells were analyzed by immunoblotting with indicated antibodies. Results represent three independent experiments.
g siRNA-mediated loss of LATS1 expression results in impaired colony formation of sorafenib-resistant Huh7 cells in response to sorafenib (Srf). Results
represent three independent experiments. h, i The expression of LATS1 (h) and LATS2 (i) was determined in the TCGA database. Expression values were
log2-transformed. Statistical analysis was calculated using two-tailed, unpaired Welch’s t-test. j, k Kaplan–Meier analysis of the TCGA database for the
expression of LATS1. Overall survival (OS) (j) and disease-free survival (DFS) (k) of high and low patients are shown. Statistical signiﬁcance was calculated
using log-rank (Mantel–Cox) test. l LATS1 expression was determined by RNA sequencing of needle biopsies from patients before sorafenib treatment and
during sorafenib treatment. mRNA levels of tumor biopsies were normalized to corresponding adjacent non-neoplastic tissue for each individual patient.
Each dot represents one patient (Pre-sorafenib: n= 3 for responders and n= 6 for non-responders; On-sorafenib: n= 4 for responders and n= 6 for non-
responders). Data represents log2 fold changes. Statistical signiﬁcance was determined by Komogorov–Smirnov t-test.
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increased LC3B puncta were observed in response to BRAFi in
LATS1, but not LATS2, knockdown cells, which were further
enhanced upon CQ treatment (Supplementary Fig. 5a, b), sug-
gesting that BRAFi-induced autophagy induction was increased
upon loss of LATS1. Analysis of autophagic ﬂux indicated that
the loss of LATS1 enhanced vemurafenib-induced p62 degrada-
tion (Supplementary Fig. 5c). Increased p62 degradation upon
loss of LATS1 could be prevented by the autophagic ﬂux inhibitor
CQ, conﬁrming an enhanced autophagic ﬂux (Supplementary
Fig. 5d). These results show that LATS1 can also restrict BRAF
inhibitor-induced autophagy in melanoma cells.
Autophagy is a cellular response to many stresses and is best
characterized under conditions of mammalian target of rapamy-
cin inhibition26. We thus assessed the functional role of LATS1 in
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rapamycin-induced autophagy in standard cellular models, such
as U2OS sarcoma cells. Indeed, immunoﬂuorescence microscopy
analysis revealed an increased number of LC3B puncta upon
LATS1 knockdown in U2OS cells, which was further increased
upon CQ treatment (Supplementary Fig. 5e, f), indicating
rapamycin-induced autophagy induction was attenuated by
LATS1. The analysis of global autophagy induction by ﬂow
cytometry analysis of LC3 signal intensity27 revealed an increase
of LC3 upon LATS1 knockdown, conﬁrming a speciﬁc restrictive
role of LATS1, but not LATS2, in rapamycin-induced autophagy
(Fig. 2f and Supplementary Fig. 5g). In line with decreased p62
protein levels upon rapamycin treatment in LATS1-knockdown
cells, cleavage of a green ﬂuorescent protein (GFP)-fused form of
LC3, a frequently used alternative assay for autophagic ﬂux
activity28,29, was also increased upon loss of LATS1, which
further supported the notion that LATS1 restricted autophagic
ﬂux (Supplementary Fig. 5h). To further validate LATS1-
mediated autophagy regulation, we assessed the autophagosome
and autolysosome dynamics in U2OS cells stably expressing a
fusion RPF-GFP-LC3 construct. Analysis of the numbers of
autophagosome (yellow) and of autolysosome (red) in response to
rapamycin or CQ or a combination of both conﬁrmed that
LATS1 restricted rapamycin-induced autophagy induction as well
as autophagic ﬂux activity (Supplementary Fig. 6a–c).
We next investigated the autophagy regulatory role of LATS1
in vivo by comparing liver-speciﬁc Lats1 conditional knockout
mice (Latsﬂ/ﬂ; Alb-cre; cKO) to control mice (Latsﬂ/ﬂ; Control). To
investigate the role of Lats1 in autophagy induction of
hepatocytes, we treated the mice with CQ and found that loss
of Lats1 resulted in higher lipidated LC3BII (Fig. 2g, h), indicating
that Lats1 efﬁciently inhibited autophagy induction in vivo. To
study the role of Lats1 in autophagic ﬂux, we treated the mice
with rapamycin followed by overnight starvation. Immunoblot-
ting for p62 in the livers of the different genotype mice revealed
lower amounts of p62 in cKO mice compared to Control mice
(Fig. 2i, j), suggesting that Lats1 also inhibited autophagic ﬂux
in vivo.
Together, the observations demonstrate a general inhibitory
role of LATS1 in autophagy regulation, either under physiological
conditions or in response to targeted therapy or rapamycin-
induced cell stress.
LATS1 interacts with and stabilizes Beclin-1. To delineate the
molecular mechanisms underlying autophagy regulation by
LATS1, we assessed whether LATS1 directly or indirectly affected
any autophagy core-machinery proteins. Beclin-1 exerts a central
role in autophagy induction and execution by orchestrating dif-
ferent autophagy complexes via direct binding to a variety of co-
factors, but also by forming inactive homo-dimers30. Given that
the LATS family kinase NDR can interact with Beclin-131, we ﬁrst
tested a potential physical interaction between LATS1 and Beclin-
1. Strikingly, LATS1 formed a complex with Beclin-1 in a kinase
activity-independent manner, as both KD and constitutively
active (PIF) versions of LATS1 interacted with Beclin-1 to a
comparable extent as WT LATS1 (Fig. 3a). By comparing LATS1
and NDR1 on Beclin-1 interaction and Srf-induced autophagy,
we found that LAST1 interacted with Beclin-1 with much higher
afﬁnity (Supplementary Fig. 7a). Although RNAi-mediated
ablation of LATS1 increased Srf-induced autophagic cell death,
loss of NDR1 barely had any effect Srf-induced autophagy
(Supplementary Fig. 7b). The LATS1-Beclin-1 protein interaction
was also observed with endogenous proteins (Fig. 3b). Impor-
tantly, an increased interaction between LATS1 and Beclin-1 was
observed in response to Srf treatment, as well as in Srf-resistant
cells, indicating a potential Srf stress-induced speciﬁc LATS1-
Beclin-1 interaction (Fig. 3c, d). Notably, the LATS1-Beclin-1
interaction substantially promoted an upregulation of Beclin-1
protein in a LATS1 dosage-dependent manner (Fig. 3e). In
striking contrast, LATS2 barely had any effect on Beclin-1 protein
stability (Supplementary Fig. 7c). Various versions of kinase-
inactive LATS1 as well as the constitutively active LATS1 PIF-
mutant stabilized Beclin-1 comparable to WT LATS1 (Supple-
mentary Fig. 7d). The use of different protein tags, either at the C-
or N-terminal end of LATS1, conﬁrmed the impact of LATS1 on
Beclin-1 stabilization (Supplementary Fig. 7e).
We next determined whether LATS1 promoted Beclin-
1 upregulation at the mRNA or protein level. Analysis of
Beclin-1 mRNA revealed no difference between control and
LATS1-knockdown cells (Supplementary Fig. 7f), yet a cyclohex-
imide pulse-chase experiment revealed that overexpressed
LATS1 stabilized Beclin-1 at the protein level (Fig. 3f, g). This
stabilizing effect was further conﬁrmed at the endogenous level,
where ablation of LATS1, but not LATS2, resulted in decreased
Beclin-1 protein levels in response to the cap-dependent protein
synthesis blockade induced by Srf (Fig. 3h). Furthermore, aging-
induced downregulation of Beclin-1 was further enhanced upon
Lats1 deﬁciency in mouse livers in vivo, indicating a speciﬁc
Lats1-mediated Beclin-1 stabilization during aging (Fig. 3i). These
ﬁndings suggested that LATS1 stabilized Beclin-1 at the
protein level.
Taken together, these results indicate that LATS1 interacts with
and stabilizes Beclin-1 protein.
Fig. 2 LATS1 restricts autophagy in a kinase activity-independent manner. a, b Immunoﬂuorescence analysis of LC3B puncta in Huh7 cells in response to
sorafenib (Srf) treatment. Cells transfected with indicated siRNAs were treated with DMSO or sorafenib (6 μM for Huh7) for 40 h and baﬁlomycin A1 (Baf;
0.1 μM) for 2 h. Representative images (a) and quantiﬁcation of LC3B puncta numbers (b) from three independent experiments are shown. Statistical
analysis was calculated by one-way ANOVA. Scale bars, 25 μm. c The forced expression of both wild-type (WT) LATS1 and a kinase-dead (KD D846A)
version of LATS1 blocks sorafenib-induced autophagic ﬂux in Hep3B cells. Results represent three independent experiments. d, e Huh7 cells transfected
with either siControl or siRNA against LATS1 were in addition transfected with empty vector (EV) or a vector encoding siRNA-refractory wild-type (WT) or
a kinase-dead (KD D846A) version of LATS1, as indicated. Representative immunoblots (d) and quantiﬁcation of the relative p62 levels (e) (normalized to
GAPDH, fold change) from three independent experiments are shown. Statistical signiﬁcance was calculated using one-way ANOVA. f Flow cytometry
analysis of autophagy induction in U2OS-GFP-LC3 cells. Cells were transfected with indicated siRNAs and then treated with rapamycin (100 nM) for 16 h
and additional chloroquine (10 μM) for 2 h. Results represent for three independent experiments. g, h Control mice (Lats1ﬂ/ﬂ; Control) or mice with a
hepatocyte-speciﬁc depletion of Lats1 (Alb-Cre;Lats1ﬂ/ﬂ; cKO) were treated with chloroquine (30mg/kg) for 4 h. Liver samples were collected and lysed for
immunoblotting analysis. An immunoblot (g) and quantiﬁcation of the relative LC3BII levels (h) (normalized to GAPDH, fold change) from n= 3 mice per
cohort are shown. Statistical signiﬁcance was calculated using two tailed, unpaired t-test. i, j Control mice (Lats1ﬂ/ﬂ; Control) or mice with a hepatocyte-
speciﬁc depletion of Lats1 (Alb-Cre;Lats1ﬂ/ﬂ; cKO) were treated with rapamycin (2 mg/kg, twice within 24 h) followed with being fasted for 12 h. Liver
samples were collected and lysed for immunoblotting analysis. An immunoblot (i) and quantiﬁcation of the relative p62 levels (j) (normalized to GAPDH,
fold change) in livers of n= 4 for control and n= 6 for cKO mice. Statistical signiﬁcance was calculated using two-tailed unpaired t-test.
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Identiﬁcation of the functional diversity between LATS1 and
LATS2. Our ﬁndings revealed a surprising functional diversity
between LATS1 and LATS2 in regulating autophagy and Beclin-1
protein stability. We thus sought to identify the molecular dif-
ference underlying these divergent functions of LATS1 and
LATS2. Using the stabilization of Beclin-1 by interacting with
LATS1 but not LATS2, we mapped the essential domain of
LATS1 required for interacting with and stabilizing Beclin-1
between amino acids 167 and 523 (Fig. 4a and Supplementary
Fig. 7g, h). Of note, sequence alignment between LATS1 and
LATS2 showed that a major part of this domain represented the
most diverse amino acid sequences between LATS1 and LATS2
(amino acids 151–554 in LATS1 and amino acids 149–513 in
LATS2, respectively). In contrast, the LATS1 kinase domain did
not seem essential. This notion was functionally conﬁrmed by
using a construct containing only the LATS1 kinase domain but
not the essential domain; the kinase domain alone failed to
repress Srf-induced autophagy (Supplementary Fig. 7i).
We examined the importance of the essential domain by
replacing this variable area of LATS2 with the comparable area
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from LATS1, generating a LATS2 chimera protein, which
contained unchanged domains of LATS2 at the N and C termini
but with a middle domain derived from LATS1 (Fig. 4b).
Interestingly, the LATS2 chimera stabilized Beclin-1 to a
comparable extent as WT LATS1, whereas WT LATS2 had no
effect (Fig. 4c). The LATS2-chimeric protein could also restore
the p62 levels that were reduced by the siRNA-mediated ablation
of LATS1 expression (Fig. 4d, e).
These data show that a small protein domain present in LATS1
but not in LATS2 is sufﬁcient to mediate the stabilization of
Beclin-1 and, thus, to repress autophagy. Since current knowledge
suggests a redundant function of LATS1 and LATS2, these results
are unexpected and identify a diverse function of the two closely
related kinases at the molecular level.
LATS1 promotes K27-ubiquitination of Beclin-1 on lysines
K32 and K263. Stabilization of proteins is frequently triggered by
their post-translational modiﬁcation, for example by ubiquitina-
tion. Beclin-1 is tightly regulated at the post-translational level by
phosphorylation, acetylation and ubiquitination30,32–34. Ubiqui-
tination of Beclin-1 generally leads either to its proteasomal
degradation or stabilization or to its activation, depending on the
speciﬁc ubiquitin linkage35.
Thus, we assessed whether LATS1 had any effect on Beclin-1
ubiquitination. Surprisingly, although LATS1 stabilized Beclin-1
protein, we found that LATS1, but not LATS2, substantially
promoted Beclin-1 ubiquitination, notably without requiring its
kinase activity (Fig. 5a). Furthermore, endogenous LATS1 also
promoted Beclin-1 ubiquitination as knockdown of LATS1
resulted in decreased ubiquitination of endogenous Beclin-1
(Fig. 5b). Consistent with its ability to stabilize Beclin-1, the
hybrid LATS2 chimera potently increased ubiquitination of
Beclin-1 (Supplementary Fig. 8a). The use of a large number of
lysine mutant versions of ubiquitin revealed that both exogenous
and endogenous LATS1-induced ubiquitination of Beclin-1
involved a lysine 27-mediated linkage of ubiquitin molecules
(Fig. 5b, c and Supplementary Fig. 8b, c, d).
To further delineate the functional role of LATS1-induced
Beclin-1 ubiquitination, we ﬁrst analyzed which protein domain
of Beclin-1 was ubiquitinated in a LATS1-dependent manner. Co-
expression of various GFP-fused domains of Beclin-1 with LATS1
and ubiquitin identiﬁed the N terminus and central coiled-coil
domain of Beclin-1 as most susceptible to LATS1-induced
ubiquitination (Fig. 5d and Supplementary Fig. 8e). Next, we
sought to map the LATS1-induced ubiquitination sites via mass
spectrometry (MS) analysis. Indeed, lysine residues 32 and 263,
which locate inside the N-terminal intrinsic disordered domain
and central coiled-coil domain, respectively, were predominantly
detected with increased levels of ubiquitination by LATS1 (Fig. 5e
and Supplementary Fig. 8f). Sequence alignment of lysine
residues K32 and K263 across different species revealed that
K263 was more conserved (Supplementary Fig. 8g), indicating
that K263 ubiquitination induced by LATS1 or homolog genes
might be a more common event.
To validate whether these two lysine residues were bona ﬁde
sites on Beclin-1, we mutated these two lysine (K32/263) residues
to arginine (R). Strikingly, while WT Beclin-1 was efﬁciently
ubiquitinated in dependence on LATS1, this ubiquitination was
greatly diminished with the K32/263R mutant version of Beclin-1
(Fig. 5f).
K27 linkage represents a largely unexplored, non-canonical
form of ubiquitination. The HECT family E3 ligase NEDD4 has
been previously reported to mediate K6, K11, and K27-linked
polyubiquitination and consequently inﬂuence the stability of
Beclin-136,37. We thus assessed whether NEDD4 play a role in
LATS1-mediated K27-linked ubiquitination on Beclin-1. First, we
conﬁrmed that the forced expression of NEDD4 stabilized Beclin-
1 protein in a dose-dependent manner (Supplementary Fig. 9a).
This NEDD4-mediated stabilization of Beclin-1 was accompanied
by its increased K27-linked ubiquitination (Supplementary
Fig. 9b). Although LATS2 interacts with Beclin-1 at a visible
lower afﬁnity in comparison with LATS1 (Supplementary Fig. 9c),
LATS2 did not have any effect on Beclin-1 ubiquitination (Fig. 5a,
c) and stability (Supplementary Fig. 7a, b). We next assessed
whether NEDD4 interaction can distinguish LATS1 and LATS2.
In line with a previous report36,38, LATS1 was also found to
physically interact with NEDD4 (Supplementary Fig. 9d).
Importantly, the interaction between LATS1 and NEDD4 was
independent of its kinase activity, but required its unique domain
not present in LATS2 (Supplementary Fig. 9d, e). Consequently,
LATS1, but not LATS2, promoted NEDD4 stability (Supplemen-
tary Fig. 9f, g). Conversely, NEDD4-LATS1 interaction led to the
degradation of LATS1 but not LATS2 (Supplementary Fig. 9g, h).
To assess whether NEDD4 directly affected LATS1-induced
Beclin-1 ubiquitination on K32/263, we analyzed the potential
NEDD4-mediated K27-ubiquitination of Beclin-1. Strikingly,
while NEDD4 potently induced K27-linked polyubiquitination
of WT Beclin-1, it failed to do so in the K32/263R mutant
(Supplementary Fig. 9i), identifying NEDD4 as a potential E3
ligase for K27-linked polyubiquitination at K32/263 of Beclin-1.
Fig. 3 LATS1 interacts with and stabilizes Beclin-1 in a kinase activity-independent manner. a HEK293T/17 cells were transfected with indicated
plasmids. Seventy-two hours later, cell lysates were immunoprecipitated with anti-HA antibody followed by immunoblotting with indicated antibodies.
Input represents lysates directly immunoblotted without immunoprecipitation. Results represent three independent experiments. b Huh7 cells were lysed
for immunoprecipitation with indicated antibodies followed by immunoblotting analysis for Beclin-1 and LATS1. Input represents lysates before
immunoprecipitation. Results represent three independent experiments. c HEK293T/17 cells transfected with indicated plasmids were treated with
sorafenib (SRF; 10 μM, 2 h) followed by immunoprecipitation with indicated antibody. Results represent three independent experiments. d Huh7p or IR or
CR cells were lysed for immunoprecipitation with indicated antibodies followed by immunoblotting analysis for Beclin-1 and LATS1. Input represents lysates
before immunoprecipitation. Results represent three independent experiments. e LATS1 promotes Beclin-1 stability in a dosage-dependent manner.
HEK293T/17 cells were transfected with same amount of vector encoding for Flag-tagged Beclin-1 together with increased amounts of vectors encoding for
Myc-tagged wild-type LATS1 or kinase-dead mutant LATS1 (KD D846A) as indicated. Seventy-two hours later, cells were lysed and analyzed by
immunoblotting for the expression of Beclin-1 (Flag) and LATS1 (Myc). Results represent three independent experiments. f, g HEK293T/17 cells
transfected with indicated plasmids were treated with cycloheximide (CHX; 40 μg/mL) for the indicated times. Representative Immunoblots was shown in
f and quantiﬁcation g of band intensity was pooled from three independent experiments. Statistical signiﬁcance was done using one-way ANOVA. **P <
0.01. Note: to achieve equal amount of Beclin-1 protein level at time point 0, amounts of Flag-Beclin-1 plasmid transfected between empty vector and LATS1
were 3:1. h Huh7 cells transfected with indicated siRNAs were treated with DMSO or sorafenib (Srf; 10 μM) for 48 h. Cell lysates were analyzed by
immunoblotting with indicated antibodies. A representative immunoblot from three independent experiments is shown. i Liver tissues from Control mice
(Lats1ﬂ/ﬂ; Control; n= 3) or mice with a hepatocyte-speciﬁc depletion of Lats1 (Alb-Cre;Lats1ﬂ/ﬂ; cKO; n= 3) were collected at young adult age
(12–16 weeks) or at old age (55–65 weeks) and lysed for immunoblotting analysis.
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Together, the results suggest that LATS1 speciﬁcally promotes
a K27-linked ubiquitination of Beclin-1 at lysine residues 32 and
263, most likely via the E3 ligase NEDD4.
Beclin-1 K32/263 ubiquitination is required for LATS1 effect.
Our observations suggest that LATS1 induces Beclin-1
stabilization and K27-linked ubiquitination at K32/263 of Beclin-
1. To determine whether this Beclin-1 ubiquitination affects its
protein stability, we directly tested the LATS1-mediated stabili-
zation of WT and mutant Beclin-1. Interestingly, while WT
Beclin-1 was potently stabilized, LATS1-mediated stabilization
was signiﬁcantly impaired with the K32/263R mutant (Fig. 6a, b).
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Fig. 4 Functional characterization of the divergence between LATS1 and LATS2. a Schematic representation of the protein domain structure and
truncated mutants of LATS1 used for mapping the LATS1 protein domain required for Beclin-1 interaction and stabilization. b Schematic illustration of the
generation of a LATS2-LATS1 chimeric protein by replacing the center domain of LATS2 (blue bracket) with the analogous domain of LATS1 (red bracket;
amino acids 151–554) inserted between the wild-type LATS2 N-terminal (amino acids 1–147) and C-terminal (amino acids 514–1088) domains. c Functional
validation of the LATS2 chimera protein in Beclin-1 stabilization. HEK293T/17 cells were transfected with the same amount of vectors encoding for Flag-
tagged Beclin-1 (Flag-BECN1) together with HA-tagged wild-type LATS1 or LATS2, or increasing amounts of vector encoding the HA-tagged LATS2-
chimeric protein as indicated. Cells were collected 72 h after transfection and analyzed by immunoblotting for Flag-BECN1, LATS1, and LATS2.
Immunoblotting for GAPDH was used as loading control. Results represent three independent experiments. d, e LATS2 chimera protein can fully rescue
autophagic ﬂux (p62) in endogenous LATS1-knockdown Huh7 cells in response to sorafenib. Huh7 cells transfected with siControl or siLATS1 were in
addition transfected with empty vector (EV) or a vector encoding for LATS2 chimera. Cells were lysed 72 h after transfection and p62 and LATS1 protein
levels were analyzed by immunoblotting. GAPDH was used as loading control. A representative immunoblot (d) and quantiﬁcation of the relative p62
levels (e) (sorafenib 8 μM condition, normalized to GAPDH) from three independent experiments are shown. Statistical signiﬁcance was calculated using
one-way ANOVA.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-13591-7 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:5755 | https://doi.org/10.1038/s41467-019-13591-7 | www.nature.com/naturecommunications 9
These results indicate that K27-linked ubiquitination of Beclin-1
on K32/263 is relevant for Beclin-1 stability.
To assess whether LATS1-induced ubiquitination of Beclin-1
had a causal role in autophagy regulation, we re-introduced
siRNA-refractory versions of either WT Beclin-1 or its K32/263R
mutant into Beclin-1 knockdown cells (Fig. 6c) and assessed
autophagy induction by Srf in HCC cells and by rapamycin in
U2OS cells. Interestingly, we observed an enhanced autophagy
induction, as reﬂected by an increased number of LC3B puncta
upon immunoﬂuorescence staining (Fig. 6d, e) or a higher
LC3 signal by ﬂow cytometry (Fig. 6f) in the Beclin-1 K32/263R
mutant as compared with WT Beclin-1. Next, we determined
autophagic ﬂux in cells expressing either WT or K32/263R
mutant Beclin-1 by analyzing p62 protein degradation in
response to Srf treatment. In line with an increased autophagy
induction, we observed higher autophagic ﬂux (Fig. 6g, h).
Although Beclin-1 generally represented an essential gene for
cell viability (Supplementary Fig. 10a), we further analyzed the
biological effects of LATS1-medated ubiquitination of Beclin-1.
In agreement with a restrictive role in autophagy, we found that
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ubiquitination deﬁciency in Beclin-1 resulted in increased cell
death and decreased long-term cell viability (Fig. 6i, j).
The results indicate that LATS1-induced ubiquitination of
Beclin-1 functionally results in Beclin-1 stabilization and, with it,
into a repression of autophagic cell death.
LATS1 induces inactive Beclin-1 dimerization. Our results
suggest a LATS1-speciﬁc role in restricting autophagy via mod-
ulating Beclin-1 protein through K27-linkage ubiquitination.
K27-linked ubiquitin bestows some unique features, which lead to
stabilization and/or dimerization/aggregation of targeted pro-
teins39–42. We thus addressed how LATS1-induced Beclin-1
ubiquitination may affect autophagy. Notably, K32 and K263 on
Beclin-1, which are ubiquitylated by NEDD4/LATS1, locate
within the N-terminal intrinsic disordered domain and coiled-coil
domain, respectively (Fig. 4d). Although the intrinsic disordered
domain is structurally unexplored, the coiled-coil domain has
been reported essential for Beclin-1 to form activating autophagy
regulatory complexes as well as inactive Beclin-1 self-dimers43.
Remarkably, an anti-parallel coiled-coil structure within a Beclin-
1 homo-dimer involves most of their coiled-coil domains (aa
175–263), where the C termini of the coiled-coil domains (aa
248–265) are critical for stabilization of the homo-dimer44.
Crystal structural studies suggest that lysine 263 is the last amino
acid of alpha helix45. Based on the stabilizing effect of LATS1 on
Beclin-1, the potential effect of K27-linked ubiquitination on
protein aggregation, and the unique position of K263 within the
C terminus of the coiled-coil domain, we assessed whether LATS1
promoted Beclin-1 self-dimerization. Indeed, LATS1 signiﬁcantly
promoted Beclin-1 self-dimer formation in a kinase-independent
manner (Fig. 7a, b). Consistent with Beclin-1 stabilization
reported above, LATS2 failed, whereas the hybrid LATS2 chimera
efﬁciently induced Beclin-1 self-dimerization (Fig. 7c, d). Finally,
LATS1-induced Beclin-1 homo-dimer formation was found
reduced with the Beclin-1 K263R mutant (Fig. 7e, f), indicating
that ubiquitylation on lysine 263 is functionally essential to
mediate the role of LATS1 in promoting Beclin-1 homo-dimer
formation and thus in preventing autophagy. Consistent with this
notion, LATS1 also repressed the formation of an active autop-
hagy initiation complex (Beclin-1/ATG14L/VPS34) (Supple-
mentary Fig. 10b).
Together, the data demonstrate that LATS1 promotes the
formation of inactivated Beclin-1 homo-dimers to prevent it from
forming pro-autophagic (Beclin-1/ATG14L/VPS34) complexes.
Thus, we report a kinase-independent function for LATS1, but
not LATS2, in preventing autophagy under physiological
conditions and in response to therapy stress and thus regulating
therapy response in HCC cells (Fig. 7g). Such pro-tumorigenic
activity is certainly an unexpected function of the well-studied
tumor suppressor LATS1, an insight that may open new avenues
to overcome therapy resistance.
Discussion
LATS1 and LATS2 kinases are evolutionarily conserved tumor
suppressors, which share ~50% and 85% amino acid sequence
identity between the full proteins and the kinase domains,
respectively. In most cellular contexts, LATS1 and LATS2 act in a
redundant manner as effector kinases of the Hippo signaling
pathway by phosphorylating and inactivating the transcription
factors YAP and TAZ21. We here report a functional divergence
between LATS1 and LATS2 by the identiﬁcation of a kinase
activity-independent scaffolding function of LATS1, but not
LATS2, in the regulation of autophagy. Although LATS1 pro-
motes cell viability in response to Srf treatment of HCC cells,
LATS2 has no effect. Analysis of autophagy modulation by
LATS1 and LATS2 further conﬁrms our observation of a speciﬁc
role of LATS1 in restricting Srf-induced lethal autophagy in HCC
cells. Subsequent mechanistic studies reveals a unique role of
LATS1, but not LATS2, in stabilizing the autophagy core-
machinery protein Beclin-1 via K27-linked ubiquitination and
self-dimerization. The distinct role between LATS1 and LATS2 in
autophagy regulation is exerted by a protein domain of LATS1
located between amino acids 167 and 524, a domain that also
represents the most divergent part between LATS1 and LATS2.
The major function of LATS kinases in Hippo signaling is to
phosphorylate the transcription factors YAP and TAZ, which
earmarks them for nuclear export, deactivation, and degradation.
On the other hand, the kinase activity-independent roles of LATS
kinases have just started to be addressed. For instance, LATS2
restricts WNT signaling activity by disrupting the BCL9/β-cate-
nin complex, which is dependent on its N-terminal domain but
not on its kinase domain46. Likewise, the N-terminal domains of
LATS1 and LATS2 are required to target ERα for DCAF-1-
mediated degradation during mammary gland lineage commit-
ment47. Interestingly, LATS1 is reported to interact with NF248,
CRL4DCAF1 49, and CDK250. Although the kinase domain is
required to interact with CRL4DCAF1 (aa 598–1130)49, the
N-terminal domain of LATS1 has been identiﬁed to mediate its
interaction with NF2 (AIxEIxxSL, aa 72–89 of LATS1)48, CDK20
(aa 1–200 of LATS1)50, and Beclin-1 (aa 154–554 of LATS1) (this
Fig. 5 LATS1 promotes Beclin-1 ubiquitination at lysine residues K32 and K263. a HEK293T/17 cells transfected with indicated plasmids were collected
72 h later for immunoprecipitation with anti-Flag antibody and then immunoblotted for HA and Flag-tagged proteins and for LATS1/2. Input represents
analysis of cell lysates before immunoprecipitation. Immunoblots represents three independent experiments. b HEK293T/17 cells were transfected with
indicated siRNAs followed by transfection with HA-tagged wild-type or K27 (all lysins were mutated to arginine except K27) ubiquitin constructs. Seventy-
two hours later, cell lysates were prepared and immunoprecipitated with Beclin-1 antibody and immunoblotted with antibodies against Beclin-1 and HA
(HA-Ub). Input represents immunoblotting of cell lysates for Beclin-1 and LATS1 before immunoprecipitation. Immunoblots represent three independent
experiments. c HEK293T/17 cells transfected with indicated plasmids. Seventy-two hours later, cell lysates were prepared and immunoprecipitated with
anti-Flag antibody and immunoblotted with antibodies against HA and Flag-tagged proteins and LATS1/2. Input represents analysis of cell lysates before
immunoprecipitation. GAPDH was used as loading control. Immunoblots represent three independent experiments. d Schematic representation of LATS1-
mediated ubiquitination levels in the different domains of Beclin-1. Note that the MID construct containing the central coiled-coil domain is the minimal
recipient domain for ubiquitination. e Mass spectrometric identiﬁcation of ubiquitination sites in Beclin-1 induced by LATS1. HEK293T/17 cells were
transfected with vectors encoding for HA-tagged wild-type ubiquitin, Flag-tagged-Beclin-1 with vectors encoding for empty vector and Myc-tagged LATS1.
After immunoprecipitation with antibodies against Flag, samples were eluted for ubiquitination site identiﬁcation by mass spectrometry. Related fold
change of ubiquitinated peptide (ratio of LATS1/empty vector) is presented. Results were pooled from ﬁve independent experiments. f Mutation of lysine
residues K32/263 blocks LATS1-induced ubiquitination of Beclin-1. Beclin-1 lysine K32 and K263 were mutated to arginine via site-directed mutagenesis.
HEK293T/17 cells were transfected with indicated plasmids. Cells were collected 72 h later for immunoprecipitation with anti-Flag antibody and then
immunoblotted for HA, Flag tagged proteins and LATS1/2. Input represents analysis of cell lysates before immunoprecipitation. Immunoblots represents
three independent experiments. Note that the different proteins have been analyzed on different membranes.
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report). These results indicate different but unique interaction
interfaces among these LATS1 complexes. Whether and how
conformation changes of LATS1 induced by its interaction with
speciﬁc binding partner affects the binding to other partners
certainly merits further biochemical investigation.
On the other hand, an interplay between the Hippo signaling
pathway and autophagy has been identiﬁed by mainly focusing
on the activity of MST kinases, the upstream regulators of LATS
activity. For instance, MST kinases regulate autophagy by directly
phosphorylating BCL2, BCL-XL and LC3B proteins51–53. LATS1
also interacts with BAG354, a BCL family member implicated in
tension-induced autophagy55. However, a direct functional con-
tribution of LATS1 to BAG3-mediated autophagy remains open.
A role of the LATS1 homolog warts (wts) in autophagy has been
described in Drosophila and Caenorhabditis elegans. Although wts
mutation leads to attenuated autophagy in the salivary glands of
the ﬂy, RNAi-mediated depletion of wts leads to degradation of
p62 in the worm56,57. These results suggest a a potential cellular
context-dependent role of wts in autophagy regulation.
Our study has used an unbiased bioinformatics analysis to
identify a restrictive role of LATS1, but not LATS2, in Srf-induced
autophagy in HCC and other cancer types and normal liver
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in vivo. Importantly, this distinct function of LATS1, but not
LATS2, in autophagy appears independent of its kinase activity.
Our data rather indicate that LATS1 acts as a scaffold to bind
Beclin-1 and to promote K27-linked ubiquitination of Beclin-1 at
lysine residues K32 and K263 in its N-terminal intrinsic dis-
ordered domain and coiled-coil domain, respectively. Conse-
quently, K27-linked ubiquitination of Beclin-1 on K32 and K263
promotes Beclin-1 stabilization, its self-dimerization, and autop-
hagy inhibition. Although increased at the protein level, in its
self-dimerized form Beclin-1 is inactivated and can no more
contribute to the execution of autophagy43, as for instance
induced by Srf treatment of HCC cells (Fig. 7g). It is noted that
NEDD4 functions as a potential ubiquitin E3 ligase in regulating
LATS1-induced ubiquitination of Beclin-1. Sequence alignment
across different species of Beclin-1 lysine residue K32 and
K263 suggests that K263 might represent evolutionary conserved
regulatory mechanism of LATS1/wts towards Beclin-1. Interest-
ingly, invertebrate genomes encode one wts kinase, whereas
vertebrate genomes encode two wts homolog kinases (LATS1 and
LATS2). Beclin-1, on the other hand, functions as a platform to
orchestrate diverse autophagy regulatory complexes29,30. Notably,
the central coiled-coil domain plays a key role in shifting Beclin-1
to different sub-complexes, such as Beclin-1/UVRAG, Beclin-1/
ATG14, or its inactive homo-dimer. In line with previous ﬁndings
of an important input of the C terminus of the coiled-coil domain
to homo-dimer formation44, our results demonstrate that lysine
residue K263 is critical for Beclin-1 homo-dimer formation,
which functionally mediates the regulatory role of LATS1 in
autophagy.
In contrast to its tumor suppressive role in the Hippo signaling
pathway, we report that LATS1 exerts a pro-survival function in
HCC cells in response to Srf treatment, i.e., an oncogenic activity.
Indeed, RNAi-mediated ablation of LATS1 expression results in
an increase of Srf-induced apoptosis and a reduction of cell via-
bility in vitro and a decrease of tumor growth in vivo. Moreover,
gene expression analysis of HCC patient samples indicates a poor
survival of patients with high expression of LATS1 in their
tumors, further supporting the notion of a pro-oncogenic role of
LATS1 in HCC cells. Most importantly, a signiﬁcant higher
expression of LATS1 is observed in patients not responding to Srf
as compared with patients responding to Srf therapy, suggesting
LATS1 as a clinically relevant biomarker for Srf sensitivity.
The therapeutic targeting of the Hippo signaling pathway is
currently under intense investigation in basic and pharmaceutical
research laboratories. Here we have identiﬁed a non-redundant
function of LATS in HCC. We have delineated the mechanistic
details of a kinase activity-independent function of LATS1 in
autophagy regulation and in tumorigenesis, thus raising a note of
caution on the therapeutic targeting of LATS kinases. Their pro-
tumorigenic and tumor suppressive roles, their non-redundant
distinct activities and their kinase activity-dependent and inde-
pendent functions need to be considered to efﬁciently interfere
with tumor progression and therapy resistance and to avoid
undesired consequences.
Methods
DNA plasmids, siRNA, and shRNA sequences and antibodies. DNA plasmids
and sequences of siRNAs used in this study are listed in Supplementary Dataset 1.
Additional information on antibodies is provided in Supplementary Dataset 2.
Cell culture, transfection, and reagents. HEK293T/17, Huh7, Hep3B, SNU423,
and SNU398 were obtained from American Type Culture Collection. Hep40 cell
line was a kind gift from Brian Carr. U2OS cell line stably expressing GFP-LC3 was
a kind gift from Carine Joffre. All the cell lines in this study were regularly con-
ﬁrmed for the absence of Mycoplasma contamination. Transfection of plasmids
into HEK293T/17 and HCC cells were carried out using jetPEI (polyPlus Trans-
fections) and Lipofectamine 3000 (Invitrogen) according to the manufacturers’
instructions, respectively. Lipofectamine RNAiMAX (Invitrogen) was used to
transfect siRNAs. To establish stable knockdown or overexpression cell lines, ret-
rovirus were produced by transfection of Platinium-A cells (Cell Biolabs) with
pBabe-retro-puro or pSuper-retro-puro constructs, respectively. Control or gene-
speciﬁc siRNAs were from Dharmacon as ON-TARGET plus SMARTpools or Set
of 4 upgrade products.
Srf was from Selleckchem (in vitro study) and LC Laboratories (in vivo study).
Baf and CQ were from Sigma.
HCC patient-derived ex vivo organoid lines. The stable HCC organoid lines used
in this study have been reported previously18. Brieﬂy, ultrasound-guided tumor
biopsies were obtained from patients undergoing diagnostic liver biopsy at the
University Hospital Basel. Written informed consent was obtained from all patients
and the study was approved by the ethics committee of the northwestern part of
Switzerland (Protocol Number EKNZ 2014-099). Tumor needle biopsy tissue was
rapidly transferred to the lab, minced, and digested with 2.5 mg/mL collagenase IV
(Sigma), 0.1 mg/mL DNase (Sigma) at 37 °C for 5 min. Digested biopsy/cell clusters
were then seeded into reduced growth factor BME2 (Basement Membrane Extract,
Type 2; Amsbio). After polymerization of BME2, expansion medium was added to
the BME2 droplets. The composition of the medium is: advanced Dulbecco’s
modiﬁed Eagle’s medium (DMEM)/F-12 (GIBCO) supplemented with 1:50 B-27
(GIBCO), 1:100 N-2 (GIBCO), 10 mM nicotinamide (Sigma), 1.25 mM N-acetyl-L-
cysteine (Sigma), 10 nM [Leu15]-gastrin (Sigma), 10 mM forskolin (Tocris), 5 mM
A83-01 (Tocris), 50 ng/mL EGF (PeproTech), 100 ng/mL FGF10 (PeproTech),
25 ng/mL HGF (PeproTech), and 10% RSpo1-conditioned medium (homemade).
Tumor organoids were passaged by dissociation with 0.25% Trypsin-EDTA
(GIBCO).
Fig. 6 LATS1-induced Beclin-1 ubiquitination is required for Beclin-1 stabilization and autophagy regulation. a, bMutation of lysine residues K32/263 in
Beclin-1 blocks LATS1-induced Beclin-1 stabilization. HEK293T/17 cells were transfected with the same amount of vector encoding for Flag-tagged wild-
type or K32/263R lysine mutant Beclin-1 together with a vector encoding for HA-tagged LATS1 or empty vector as indicated. Seventy-two hours later cells
were analyzed by immunoblotting with indicated antibodies. Representative immunoblots (a) and quantiﬁcation of the relative Flag-tagged Beclin-1 (b)
(normalized to GAPDH) from three independent experiments are shown. Statistical signiﬁcance was calculated using one-way ANOVA. c Huh7 cells were
transfected with indicated siRNAs followed by transfection with HA-tagged siRNA-refractory wild-type or K32/263R lysine mutant Beclin-1 cDNAs. Cells
were analyzed by immunoblotting with indicated antibodies. Results represent three independent experiments. d, e Huh7 cells were transfected with
indicated siRNAs followed with siRNA-refractory wild-type or K32/263R mutant Beclin-1 cDNAs. Cells were then treated with DMSO or sorafenib
(Srf; 6 μM for Huh7) for 24 h and/or in combination with chloroquine (CQ; 20 μM) for 2 h before ﬁxation. Representative images (d) and quantiﬁcation of
LC3B-puncta numbers (e) pooled from three independent experiments are shown. Statistical analysis was calculated by one-way ANOVA. Scale bars,
25 μm. f U2OS-GFP-LC3 Cells were transfected with indicated siRNAs followed with siRNA-refractory wild-type or K32/263R lysine mutant Beclin-1
cDNAs. Cells were then treated with rapamycin (Rapa; 100 nM) for 16 h and/or in combination with chloroquine (CQ; 10 μM) for 2 h before analysis.
Results represent three independent experiments. g, h Huh7 cells were transfected with indicated siRNAs followed with siRNA-refractory wild-type or
K32/263R lysine mutant Beclin-1 cDNAs. Cells were then treated with sorafenib for 24 h. Cells were analyzed by immunoblotting. Representative images
(g) and quantiﬁcation of relative p62 levels (h, treated with DMSO or 6 μM sorafenib) pooled from three independent experiments are shown. Statistical
analysis was calculated by one-way ANOVA. Scale bars, 25 μm. i, j Cells were transfected with indicated siRNAs followed with siRNA-refractory wild-type
or K32/263R mutant Beclin-1 cDNAs. i Cells then treated with sorafenib (Srf; 6 μM) for 48 h for immunoblotting (i) or for 7–10 days for colony formation
assays (j). Results represent three independent experiments.
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Srf treatment of tumor organoids. One thousand cells per well were seeded in a
384-well plate and Srf added 24 h later. After 6 days of drug treatment, cell viability
was assessed with CellTiterGlo 3D according to the manufacturer’s instructions.
Autophagy study in vivo. Mice carrying ﬂoxed alleles of Lats1 (Lats1ﬂ/ﬂ) were
kindly provided by Randy L. Johnson (M.D. Anderson Cancer Center) via Georg
Halder (VIB-KU Leuven Center for Cancer Biology). Mice expressing liver-
speciﬁc-cre recombinase (Alb-cre) driven by the albumin promoter (JAX stock
#003574) was kindly provided by Markus H. Heim. Lats1 conditional knock mice
(Lats1ﬂ/ﬂ, Alb-cre) were generated by crossing Lats1ﬂ/ﬂ mice with Alb-cre mice in a
C57BL/6J background. Mice were bred and maintained under speciﬁc and
opportunistic pathogen-free (SOPF) facility with food and water ad libitum. All
in vivo experiments were performed under approval number 2839 within the Swiss
Federal Animal Welfare Law.
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To block autophagic ﬂux, mice were intraperitoneally (i.p.) injected with CQ
(30 mg/kg in phosphate-buffered saline, PBS) and liver tissues were collected for
analysis 4 h after injection. To induce autophagic ﬂux, mice were i.p. injected with
rapamycin (2 mg/kg in PBS containing 5% PEG400/5% Tween-80/4% ethanol)
twice a day (0600 and 1800 h) followed by fasting for 12 h and extraction of liver
tissue for analysis.
Cloning. To establish the hybrid LATS2 chimera construct, the LATS2 N terminus
(amino acids 1–148), LATS1 domain (amino acids 151–554), and LATS2 C ter-
minus (amino acids 514–1088) were PCR-ampliﬁed and assembled into pcDNA3-
derived vectors using NEB Builder HiFi kit (NEB).
Cell viability and colony formation assays. Short-term cell viability was mea-
sured using CellTiter-Fluor cell viability assay (Promega) with a SpectraMAX plate
reader according to the manufacturer’s instructions. Viability of ex vivo organoid
lines in response to Srf was determined according to the protocol described in
ref. 18. Long-term cell viability and proliferation was performed using colony
formation assays. Brieﬂy, 200–1000 cells seeded in triplicate on 12-well plates were
cultured for 2–3 weeks. Completed culture medium supplemented with Srf or
DMSO (dimethyl sulfoxide) was refreshed every 3 days for the ﬁrst week and every
2 days from the second week onwards. To visualize differences in cell growth,
crystal violet staining was performed. Brieﬂy, cells were ﬁxed with 4% paraf-
ormaldehyde for 20 min at room temperature, washed twice with H2O, and stained
with crystal violet (1 mg/mL dissolved in 10% ethanol) for 20 min. After washing
with H2O, plates were left to dry at room temperature. The cell stained crystal
violet was retrieved with 10% acetic acid and absorbance at 595 nm was measured
using a SpectraMAX plate reader.
Tumor transplantation and Srf therapy. NSG mice were maintained in SOPF
facility with food and water ad libitum. Huh7 cells (5 × 105 in 200 μL DMEM:
Matrigel (1:1 ratio)) were implanted into the left ﬂanks. When tumors were
palpable, mice were randomly grouped into vehicle or Srf treatment cohorts. When
tumor volumes reached 100 mm3, Srf (30 mg/kg) or vehicle control was admini-
strated daily via oral gavage for 4 weeks. Tumor diameters were measured
twice a week using a caliper, and tumor volumes were calculated as follows:
volume= d2*D/2, where d and D is the shorter and longer tumor diameter,
respectively. All in vivo experiments were performed under approval number 2839
within the Swiss Federal Animal Welfare Law.
Analysis of autophagy. For LC3B staining, cells were transfected and seeded on
glass coverslips. After treatment, cells were washed in PBS and ﬁxed with ice-cold
methanol for 20 min. After PBS washes, ﬁxed cells were incubated in 0.1% Triton
X-100 in PBS for 5 min, followed by blocking with 0.1% Trition X-100 in 3%
bovine serum albumin (BSA) for 1 h. Endogenous LC3B were detected by incu-
bation of ﬁxed cells with anti-LC3B antibody (CST3868, 1:200) overnight, followed
with anti-rabbit Alexa 488 secondary antibody (Invitrogen 1:300). After 4′,6-dia-
midino-2-phenylindole (DAPI) staining, cells were washed and mounted in
ﬂuorescence mounting medium (Dako S3023). Images were acquired on a Leica
DMI 4000 microscope. For quantiﬁcations, more than 5 ﬁelds (at least 100 cells in
total) were randomly selected based on DAPI staining and the number of LC3B
dots per cell was quantiﬁed using ImageJ software.
Autophagy detection using ﬂow cytometry was performed according to the
protocol described in ref. 27. Brieﬂy, U2OS-GFP-LC3 cells were trypsinized and
incubated with 0.5% saporin in PBS for 5 min. Cells were washed and suspended
for analysis using a BD FACS Canto II ﬂow cytometer. Data were analyzed with
Flowjo software.
Protein lysis, immunoprecipitation, ubiquitination, and immunoblot analysis.
Cells were lysed with RIPA buffer (Sigma R0278) supplemented with additional 2%
NP-40. Cell lysates were sonicated before protein concentration determination
(BCA protein assay kit, Pierce 23225). Equal amount of protein was fractionated by
SDS-polyacrylamide gel eletrophoresis and transferred onto a polyvinylidene
diﬂuoride membrane, which was blocked with 5% milk in Tris-buffered saline
(TBS) followed with desired antibodies in 5% BSA-TBS. The protocol for co-
immunoprecipitation has been described previously58. Brieﬂy, cells were lysed with
Cell Signaling Technology (CST) lysis buffer (CST9803) supplemented with 1 mM
phenylmethylsulfonyl ﬂuoride and incubated with speciﬁc antibodies with protein
A/G-Sepharose overnight. After three times washing with CST lysis, the pre-
cipitated proteins were eluted with SDS-loading buffer and analyzed by immu-
noblotting. For the ubiquitination assay, cells transfected with plasmids were lysed
with RIPA buffer supplemented with additional 0.1% SDS to a ﬁnal concentration
of 0.2% SDS, followed by standard immunoprecipitation protocols. Chemilumi-
nescence was detected with X-Ray ﬁlms or Fusion FX (Analis). Image J software
was used to quantify the immunoblots by densitometry. Information on the
antibodies used is presented in Supplementary Dataset 2.
Identiﬁcation of ubiquitination sites by mass spectrometry. MS analysis was
performed in the proteomics core facility of the Biozentrum, University of Basel.
Brieﬂy, HEK cells were transfected with Flag-tagged Beclin-1 and HA-tagged
ubiquitin together with either empty vector or vector encoding LATS1. After lysis
and immunoprecipitation, proteins were eluted with 600 µl 100 mM trimethyla-
mine, pH 11. The eluate was dried in a SpeedVac and fully resuspended in 100 μL
of 50 mM Tris-HCl (pH 7.5) with sonication. Samples were heated up for 10 min
and cooled down followed by incubated with chloroacetamide (1 μL per samples).
Proteins were subjected to endoproteinase LysC (1:100 (w/w), Wako) digestion at
37 °C for 4 h, then subjected to trypsin digestion (0.5 μg/μL; 1:50; w/w) at 37 °C
overnight. The samples were then subjected to liquid chromatography–tandem MS
(LC-MS/MS).
The acquired raw-ﬁles were imported into the Progenesis QI software (v2.0,
Nonlinear Dynamics Limited), which was used to extract peptide precursor ion
intensities across all samples applying the default parameters. The generated mgf-
ﬁles were searched using MASCOT (Version: 2.4.1) against a decoy database
containing normal and reverse sequences of the predicted SwissProt entries of
Homo sapiens (www.ebi.ac.uk, release date 2016/25/05) and commonly observed
contaminants (in total 41,170 sequences for Homo sapiens) generated using the
SequenceReverser tool from the MaxQuant software (Version 1.0.13.13). The
search criteria were set as follows: semi tryptic speciﬁcity was required (cleavage
after lysine or arginine residues, unless followed by proline); four missed cleavages
were allowed; carbamidomethylation (C) was set as ﬁxed modiﬁcation; oxidation
(M) and GlyGly (K) were applied as variable modiﬁcations; mass tolerance of 10 p.
p.m. (precursor) and 0.02 Da (fragments). The database search results were ﬁltered
using the ion score to set the false discovery rate (FDR) to 1% on the peptide and
protein level, respectively, based on the number of reverse protein sequence hits in
the datasets. The relative quantitative data obtained were normalized and
statistically analyzed using our in-house script as above59. In addition, Scaffold
(version Scaffold_4.8.7, Proteome Software Inc., Portland, OR) was used to validate
MS/MS based peptide and protein identiﬁcations. Peptide identiﬁcations were
accepted if they could be established at greater than 93.0% probability by the
Scaffold Local FDR algorithm. Protein identiﬁcations were accepted if they could
be established at greater than 98.0% probability to achieve an FDR < 1.0% and
contained at least two identiﬁed peptides. Protein probabilities were assigned by the
Protein Prophet algorithm60. Proteins that contained similar peptides and could
not be differentiated based on MS/MS analysis alone were grouped to satisfy the
principles of parsimony.
Fig. 7 LATS1 induces inactive Beclin-1 self-dimerization. a LATS1, but not LATS2, promotes Beclin-1 self-dimerization in a kinase activity-independent
manner. HEK293T/17 cells were transfected with indicated plasmids. Cells were collected 72 h later for immunoprecipitation with anti-HA antibody and
then immunoblotted for HA, Flag-tagged Beclin-1, and LATS1/2. Input represents analysis of cell lysates before immunoprecipitation. Immunoblots
represent three independent experiments. b Quantiﬁcation of dimerized Beclin-1 (BECN1) protein abundancy pooled from four independent experiments
described in (a). Statistical signiﬁcance was calculated using one-way ANOVA. ***P < 0.001. c LATS2 chimera maintains the ability to promote Beclin-1
self-dimerization. HEK293T/17 cells were transfected with Flag-tagged (Flag-BECN1) and with HA-tagged (HA-BECN1) Beclin-1 and with empty vector
(EV) or with vectors encoding for wild-type (WT) LATS1 or LATS2, or LATS2 chimera, as indicated. Cells were collected 72 h later for immunoprecipitation
with anti-Flag antibody and then immunoblotted for HA, Flag-tagged Beclin-1, and LATS1/2. Input represents analysis of cell lysates before
immunoprecipitation. Immunoblots represent three independent experiments. d Quantiﬁcation of dimerized Beclin-1 (BECN1) protein abundancy pooled
from four independent experiments described in c. Statistical signiﬁcance was calculated using one-way ANOVA. *P < 0.05. e LATS1-induced ubiquitination
at lysine 263 is essential for LATS1-mediated promotion of Beclin-1 self-dimerization. HEK293T/17 cells were transfected with indicated plasmids. Cells
were collected 72 h later for immunoprecipitation with anti-Flag antibody and then immunoblotted for HA, Flag-tagged Beclin-1, and LATS1. Input
represents analysis of cell lysates before immunoprecipitation. Immunoblots represent three independent experiments. f Quantiﬁcation of dimerized
Beclin-1 (BECN1) protein abundancy pooled from three independent experiments described in e. Statistical signiﬁcance was calculated using one-way
ANOVA. ***P < 0.001, *P < 0.05. g Schematic representation of the role of LATS1 in canonical Hippo signaling (left side) and of its non-canonical role in
repressing sorafenib-induced autophagy (right side). LATS1-induced K27-linked ubiquitination of Beclin-1 on K32 and K263 results into its inactivation by
self-dimerization and thus to an inhibition of autophagy.
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RNA extraction and sequencing analysis. RNA from siRNA-transfected and Srf-
treated cells was extracted in biological triplicates using miRNeasy Mini kit
(Qiagen) according to the manufacturer’s instructions. RNA quality control was
performed using a fragment analyser and the standard or high-sensitivity RNA
analysis kits (Labgene; DNF-471-0500 or DNF-472-0500). RNA concentrations
were measured using the Quanti-iTTM RiboGreen RNA assay Kit (Life Technol-
ogies/Thermo Fisher Scientiﬁc). A total of 200 ng of RNA was utilized for library
preparation with the TruSeq stranded total RNA LT sample prep Kit (Illumina).
Poly-A+ RNA was sequenced with HiSeq SBS Kit v4 (Illumina) on an Illumina
HiSeq 2500 using protocols deﬁned by the manufacturer.
Single-end RNA-seq reads (81-mers) were mapped to the human genome
assembly, version hg19 (GRCh37.75), with RNA-STAR61, with default parameters
except for allowing only unique hits to genome (outFilterMultimapNmax= 1)
and ﬁltering reads without evidence in spliced junction table (outFilterType
= “BySJout”). Expression levels per gene (counts over exons) for the RefSeq mRNA
coordinates from UCSC (genome.ucsc.edu, downloaded in December 2015) were
quantiﬁed using qCount function from QuasR package (version 1.12.0). The
differentially expressed genes were identiﬁed using the edgeR package (version
3.14.0). Genes with p-values smaller than 0.05 and minimum log2 fold changes of
±0.58 were considered as differentially regulated and were used for downstream
functional and pathway enrichment analysis.
Functional enrichment analysis. We performed functional enrichment analysis of
differentially expressed genes for biological processes or pathways in R using
several publicly available Bioconductor resources including org.Hs.eg.db (ver-
sion 3.3.0), GO.db (version 3.4.1), GOstats (version 2.42.0)62, KEGG.db (version
3.2.3), and ReactomePA (version 1.16.2)63. The signiﬁcance of each biological
processes or pathways identiﬁed was calculated using the hypergeometric test
(equivalent to Fisher’s exact test) and those with p-values ≤ 0.05 were considered
signiﬁcant.
Gene set enrichment analysis. The GSE A analysis was performed using the
JAVA application of the Broad Institute version 3.0 (http://www.broadinstitute.org/
gsea). The gene sets used for the analysis were derived from GO annotations, and
pathways were obtained from the GO (http://www.geneontology.org/) and KEGG
(http://www.genome.jp/kegg/) databases.
Patient material and ethics. All relevant ethical regulations were strictly followed
in this study. All the analysis using human tissue samples reported in this study
were approved by the ethics commission of Northwestern Switzerland (EKNZ,
approval number 361/12).
Re-analysis of transcriptomic proﬁling data. RNA-seq gene expression values
were retrieved from om TCGA Liver dataset64 using the cbioportal (http://www.
cbioportal.org, accessed 12/05/2017) website65. The dataset included 364 and 314
HCCs with overall survival and disease-free survival information, respectively.
Survival analyses were performed using the Kaplan–Meier method and the log-
rank test. The cut-off was deﬁned as previously described66.
Statistical analysis. All statistical tests were two-sided. Speciﬁc details on the
statistical method are provided in each ﬁgure legend. Data are presented as mean.
Bar plots with error bars represent mean ± SD. Statistical signiﬁcance was deﬁned
as *P < 0.05, **P < 0.01, ***P < 0.001. All analyses were performed using Excel or
Graphpad Prism 6.0 (Graphpad Software, Inc., La Jolla, CA) or SPSS v.20 (End-
icott, New York, NY).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The mass spectrometry proteomics data have been deposited to the ProteomeXchange
Consortium via the PRIDE partner repository with the dataset identiﬁer PXD013159 and
10.6019/PXD013159. The RNA-seq ﬁles are deposited on GEO database with an
accession number GSE117116. Data sets with accession numbers GSE71873 and Uniprot
access numbers
Q14457 for human,
O8859 for Mouse,
F1RCP1 for Fish,
Q4A1L3 for Frog,
Q22592 for Worm,
Q9VCE1 for ﬂy,
Q02948 for yeast,
and TCGA Liver datasets have been used in the study.
The source data underlying Figs. 1a, c-d, f, i, 2b-e and g-h, 3a-i, 4c-e, 5a-c and e-f, 6a-c,
e and g-i, 7a-f, and Supplementary Figs. 1a-c, e-g, k and l-n, 3b-g, 4a-e and g, 5b-d, f, h,
6c, 7a-i, 8a-d and f, 9a-i, and 10c are provided in Source Data ﬁle.
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